sotorasib
amgen
['sotorasib', 'lumakras', 'lung', 'amgen']
 on may 28, 2021 the fda approved lumakras (sotorasib) from amgen inc. as the first treatment for adult patients with non-small cell lung cancer whose tumors have a genetic mutation kras g12c and who have received at least one prior systemic therapy.